Effect of endothelin-1 on human platelet shape change: Reversal of activation by naftidrofuryl

Platelets

Volumn 11, Issue 5, 2000, Pages 272-277

  Jagroop, I A ^a   Mikhailidis, D P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NAFTIDROFURYL OXALATE; SEROTONIN;

ADULT; ARTICLE; CLAUDICATION; CONTROLLED STUDY; HUMAN; INHIBITION KINETICS; NORMAL HUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ANOMALY; THROMBOCYTE RICH PLASMA; THROMBOCYTE SHAPE; THROMBOCYTE VOLUME; VASOCONSTRICTION;

MOROCCAN PEPPER VIRUS;

EID: 0033830999     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100050129288     Document Type: Article

References (48)

1. Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture
2. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
3. The paracrine endothelin system: Pathophysiology and implications in clinical medicine
4. Endothelin influences phi of human platelets through protein kinase C mediated pathways
5. Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells
6. Increased plasma concentrations of endothelin-1 in acute myocardial infarction
7. Plasma endothelin levels in hypertension and chronic renal failure
8. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and non-diabetic patients with chronic arterial obstructive disease of the lower limbs
9. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and non-diabetic patients with chronic arterial obstructive disease of the lower limbs
10. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
11. Autocrine-paracrine endothelin systems in the pathology teroid-secreting tissues
12. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
13. Measurement of platelet volume using a channelyzer: Assessment of the effect of agonists and antagonists
14. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets
15. Shape change in human platelet-measurements with a channelyzer and visualisation by electron microscopy
16. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models
17. Doxazosin a selective α(1)-adrenoceptor antagonist, also inhibits serotonin-induced shape change in human platelets
18. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin induced platelet shape change and does not enhance spontaneous platelet aggregation
19. Effect of milrinone on human platelet shape change, aggregation and thromboxane A(2) synthesis: An in vitro study
20. Angiotensin II has the capacity to induce platelet shape change which is inhibited by Iosartan
21. An investigation into the effects of bacterial lipopolysaccharide on human platelets
22. Evidence for in vivo platelet activation following the injection of conventional unfractionated heparin
23. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease
24. Evidence that naftidrofuryl is an endothelin antagonist
25. Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: Role of ET(A) receptors and platelet-activating factor
26. Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1
27. Relationships between the endothelin and nitric oxide pathways
28. Endothelin inhibits serotonin-induced platelet aggregation via a mechanism involving protein kinase C
29. Activation of endothelin B receptor causes a dose-dependent accumulation of cyclic GMP in human platelets
30. The in vitro effect of endothelin-1 on collagen, and ADP-induced aggregation in human whole blood and platelet rich plasma
31. Effects of endothelin-1 on aggregation of normal and uremic platelets
32. Role of protein kinase C in the anti-aggregatory effects of endothelin-1 on human platelets
33. Platelet aggregation in young men with contrasting predisposition to high blood pressure
34. Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats
35. Endothelin-1 evoked an increase and oscillations in cytosolic calcium concentration in adherent single human platelets and increased GMP-140 (P-selectin) in platelet suspension
36. Lipids and endothelial function: Effects of lipid-lowering and other therapeutic interventions
37. Endothelin-1 and human platelet activity
38. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF
39. Subtypes of endothelin ET(A) and ET(B) receptors mediating venous smooth muscle contraction
40. Potential role of endothelin and nitric oxide in physiology and pathology of the lower urinary tract
41. Endothelin and erectile dysfunction: A target for pharmacological intervention?
42. Upregulation of endothelin-A receptor sites in rabbit diabetic kidney: Potential relevance to the early pathogenesis of diabetic nephropathy
43. Down-regulation of endothelin-B receptor sites in cavernosal tissue of hypercholesterolaemic rabbits
44. Alterations in endothelin-B receptor sites in cavernosal tissue of diabetic rabbits: Potential relevance to the pathogenesis of erectile dysfunction
45. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for post-operative infrainguinal graft stenosis
46. Platelet activation and serotonin release during colorectal surgery
47. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease
48. The paracrine endothelin system: Pathophysiology and implications in clinical medicine